STK11 and neoplasm: In another study pulling data from several phase I/II trials, treatment with durvalumab (with or without tremelimumab) was associated with shorter patient OS and lower tumor response rates in patients with LKB1-mutated, advanced non-squamous NSCLC when compared to patients with LKB1 wild-type tumors [42].